RICHMOND, Calif., June 21, 2017 /PRNewswire/ -- Sangamo
Therapeutics, Inc. (Nasdaq: SGMO) announced today the pricing of an
underwritten public offering of 10,000,000 shares of its common
stock at a price to the public of $7.25 per share. All of the shares are being sold
by Sangamo. The gross proceeds to Sangamo from the offering, before
deducting the underwriting discounts and commissions and other
offering expenses, are expected to be $72.5
million. In connection with this offering, Sangamo granted
to the underwriters a 30-day option to purchase up to an additional
1,500,000 shares of common stock. Sangamo intends to use the
proceeds from this offering for working capital and other general
corporate purposes, including support for the continuing research
and development of its genomic therapy product candidates and
research programs, clinical trials, commercialization activities,
business development activities and, if opportunities arise,
acquisitions of businesses, products, technologies or licenses that
are complementary to Sangamo's business. The offering is expected
to close on or about June 26, 2017,
subject to customary closing conditions.
Cowen and Company, LLC and Wells Fargo Securities, LLC are
acting as joint book-running managers for the offering.
A shelf registration statement on Form S-3 relating to the
public offering of the shares of common stock described above was
filed with the Securities and Exchange Commission (the "SEC") and
is effective. The offering is being made solely by means of a
prospectus supplement and accompanying prospectus. Copies of the
final prospectus supplement and accompanying prospectus may be
obtained, when available, from the offices of Cowen and Company,
LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
Edgewood, NY, 11717, Attn:
Prospectus Department, or by calling (631) 274-2806, or from Wells
Fargo Securities, LLC, Attention: Equity Syndicate Department, 375
Park Avenue, New York, New York
10152, or by telephone at (800) 326-5897 or email to
cmclientsupport@wellsfargo.com. Electronic copies of the
final prospectus supplement and accompanying prospectus will also
be available on the website of the SEC at http://www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of these securities, nor will
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale is not
permitted.
About Sangamo
Sangamo Therapeutics, Inc. is focused on translating
ground-breaking science into genomic therapies that transform
patients' lives using the company's industry leading platform
technologies in genome editing, gene therapy, gene regulation and
cell therapy.
Forward Looking Statements
This press release may contain forward-looking statements
based on Sangamo's current expectations. These forward-looking
statements include, without limitation, the anticipated closing of
the public offering of shares of common stock and use of proceeds
from the offering. Actual results may differ materially
from these forward-looking statements due to a number of factors,
including uncertainties relating to the completion of the
public offering on the terms to which Sangamo has agreed or at all,
market conditions and the satisfaction of customary closing
conditions related to the public offering. You should not
place undue reliance on these forward-looking statements, which
apply only as of the date of this press release. Additional risks
and uncertainties relating to Sangamo and its business can be found
under the heading "Risk Factors" in Sangamo's Registration
Statement on Form S-3, as amended, initially filed with the SEC on
May 26, 2017. Sangamo assumes no
obligation to update the forward-looking information contained in
this press release.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-pricing-of-725-million-public-offering-of-common-stock-300477253.html
SOURCE Sangamo Therapeutics, Inc.